MedPath

Irisin Expression and Gene Polymorphism With Peripartum Cardiomyopathy.

Conditions
Peripartum Cardiomyopathy
Registration Number
NCT04927715
Lead Sponsor
Sohag University
Brief Summary

this is an observertional study aimed at Study the association between the level of irisin expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism in female patients with peripartum cardiomyopathy.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
45
Inclusion Criteria
  • This study will include females aged between 18 and 45 years old who have been diagnosed and treated clinically for peripartum cardiomyopathy
Exclusion Criteria
  • Age less than 18 or more than 45 year old
  • females with dilated cardiomyopathy due to other etiology or outside the time frame of occurrence of peripartum cardiomyopathy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Irisin level4 months

detect the serum level of irisin hormone by ELIZA in nanogram/decilitre(ng/dl)

FNDC5 Genotyping4 months

whether homogenetic or heterogenetic

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Sohag uniersity hosoital

🇪🇬

Sohag, Egypt

© Copyright 2025. All Rights Reserved by MedPath